These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 8929482)

  • 1. Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients.
    Kurtin PJ; Dewald GW; Shields DJ; Hanson CA
    Am J Clin Pathol; 1996 Nov; 106(5):680-8. PubMed ID: 8929482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q.
    Smoley SA; Fink SR; Paternoster SF; Stockero KJ; Nguyen LP; Nguyen PL; Hanson CA; Dewald GW
    Cancer Genet Cytogenet; 2007 Mar; 173(2):144-9. PubMed ID: 17321330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients With a History of Chemotherapy and Isolated del(20q) With Minimal Myelodysplasia Have an Indolent Course.
    Courville EL; Singh C; Yohe S; Linden MA; Naemi K; Berger M; Ustun C; McKenna RW; Dolan M
    Am J Clin Pathol; 2016 Apr; 145(4):459-66. PubMed ID: 27124938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related myeloid neoplasms with isolated del(20q): comparison with cases of de novo myelodysplastic syndrome with del(20q).
    Kanagal-Shamanna R; Yin CC; Miranda RN; Bueso-Ramos CE; Wang XI; Muddasani R; Medeiros LJ; Lu G
    Cancer Genet; 2013; 206(1-2):42-6. PubMed ID: 23357231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical course of patients with incidental finding of 20q- in the bone marrow without a morphologic evidence of myeloid neoplasm.
    Jawad MD; Shi M; Oliveira JL; Hoyer JD; Christopher Hook C; Go RS
    Am J Hematol; 2016 Jun; 91(6):556-9. PubMed ID: 26928533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 20q deletion: a recurrent cytogenetic abnormality in patients with chronic myelogenous leukemia in remission.
    Sun J; Yin CC; Cui W; Chen SS; Medeiros LJ; Lu G
    Am J Clin Pathol; 2011 Mar; 135(3):391-7. PubMed ID: 21350093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of del(20q) in patients with hematological malignancies.
    Brezinová J; Zemanová Z; Ransdorfová S; Sindelárová L; Sisková M; Neuwirtová R; Cermák J; Michalová K
    Cancer Genet Cytogenet; 2005 Jul; 160(2):188-92. PubMed ID: 15993278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited.
    Liu YC; Ito Y; Hsiao HH; Sashida G; Kodama A; Ohyashiki JH; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Nov; 171(1):9-16. PubMed ID: 17074585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.
    Huh J; Tiu RV; Gondek LP; O'Keefe CL; Jasek M; Makishima H; Jankowska AM; Jiang Y; Verma A; Theil KS; McDevitt MA; Maciejewski JP
    Genes Chromosomes Cancer; 2010 Apr; 49(4):390-9. PubMed ID: 20095039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of the del(20q) chromosome in hematologic disorders.
    Aatola M; Armstrong E; Teerenhovi L; Borgström GH
    Cancer Genet Cytogenet; 1992 Aug; 62(1):75-80. PubMed ID: 1521239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interphase FISH does not improve the detection of DEL(5q) and DEL(20q) in myelodysplastic syndromes.
    Douet-Guilbert N; Herry A; LE Bris MJ; Guéganic N; Bovo C; Morel F; DE Braekeleer M
    Anticancer Res; 2011 Mar; 31(3):1007-10. PubMed ID: 21498729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The characteristics and prognostic analysis in 213 myeloid malignancy patients with del(20q): a report of a single-center case series.
    Pan J; Wu C; Xue Y; Qiu H; Chen S; Zhang J; Bai S; Wu Y; Wang Y; Shen J; Gong Y
    Cancer Genet; 2014 Mar; 207(3):51-6. PubMed ID: 24699042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isochromosome of a deleted 20q: a rare but recurrent chromosome abnormality in myelodysplastic syndromes.
    Saunders K; Czepulkowski B; Sivalingam R; Hayes JP; Aldouri M; Sekhar M; Cummins M; Ho A; Mufti GJ
    Cancer Genet Cytogenet; 2005 Jan; 156(2):154-7. PubMed ID: 15642396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes.
    Nacheva E; Holloway T; Carter N; Grace C; White N; Green AR
    Cancer Genet Cytogenet; 1995 Apr; 80(2):87-94. PubMed ID: 7736443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Report of ten cases of hematologic malignancies with idic(20q-) and literature review].
    Han YS; Xue YQ; Li TY; Zhang J; Chen SN; Pan JL; Wu YF; Wang Y; Shen J
    Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):17-20. PubMed ID: 21429395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells.
    Yin CC; Tang G; Lu G; Feng X; Keating MJ; Medeiros LJ; Abruzzo LV
    Mod Pathol; 2015 Aug; 28(8):1130-7. PubMed ID: 25953391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.
    Liu YC; Miyazawa K; Sashida G; Kodama A; Ohyashiki K
    Cancer Genet Cytogenet; 2006 Aug; 169(1):69-72. PubMed ID: 16875940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.
    Stoner SA; Yan M; Liu KTH; Arimoto KI; Shima T; Wang HY; Johnson DT; Bejar R; Jamieson C; Guan KL; Zhang DE
    Blood; 2019 Nov; 134(20):1730-1744. PubMed ID: 31434702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
    Braun T; de Botton S; Taksin AL; Park S; Beyne-Rauzy O; Coiteux V; Sapena R; Lazareth A; Leroux G; Guenda K; Cassinat B; Fontenay M; Vey N; Guerci A; Dreyfus F; Bordessoule D; Stamatoullas A; Castaigne S; Terré C; Eclache V; Fenaux P; Adès L
    Leuk Res; 2011 Jul; 35(7):863-7. PubMed ID: 21396711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of chromosome 20q deletions in bone marrow metaphases but not peripheral blood granulocytes in patients with myeloproliferative disorders or myelodysplastic syndromes.
    Asimakopoulos FA; Holloway TL; Nacheva EP; Scott MA; Fenaux P; Green AR
    Blood; 1996 Feb; 87(4):1561-70. PubMed ID: 8608248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.